Carsten Müller-Tidow
机构: Professor of Medicine, University Hospital Heidelberg
每年引用次数
引用次数
引用: 31,501
H-指数: 86
I10-指数 : 387
出版物: 1,160
A Multicentre Phase II Study of the Aminopeptidase Inhibitor, CHR- 2797, in the Treatment of Elderly and/or Previously Treated patients with Acute Myeloid Leukemia.
B. Lowenberg , F. Davies , C. Müller-Tidow , Ulrich Dührsen
Blood 112 ( 11) 961 -961
4
2008
Genomic Changes Associated with Leukemic Transformation of Myeloproliferative Disorders.
Nils Heinrich Thoennissen , Norihiko Kawamata , Terra L Lasho , Tamara Weiss
Blood 112 ( 11) 3371 -3371
2008
Frequent in Vivo redundancy of C/EBPβ and C/EBPε during Myeloid Development
Nils Heinrich Thoennissen , Tadayuki Akagi , Sam Abbassi , Daniel Nowak
Blood 112 ( 11) 2440 -2440
2008
Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial
C. Müller-Tidow , Gesine Bug , Richard Schlenk , Michael Lübbert
Blood 112 ( 11) 2973 -2973
5
2008
Expression of Circadian Core Clock Gene Per2 Is Markedly Down-Regulated in Diffuse Large B-Cell Lymphoma
Nils Heinrich Thoennissen , Qi Cao , BaoNgan Doan , Sam Abbassi
Blood 112 ( 11) 4470 -4470
2008
ChIP-on-Chip Analysis Using Dominant Negative Form of PAX5 Fusion Gene Revealed Genes Associated with Tumorigenesis Were Directly Regulated by PAX5 in a Human B Cell Line, NALM6
Norihiko Kawamata , Fabienne Isken , Stefanie Goellner , C. Müller-Tidow
Blood 112 ( 11) 3585 -3585
2008
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)
Thomas Kindler , Frank Breitenbuecher , Stefan Kasper , Eli Estey
Blood 105 ( 1) 335 -340
89
2005
Tumor laterality influences the prognostic impact of Bcl-2 expression in curatively resected NSCLC patients
Carsten Mueller-Tidow , Martin Schuler , Lars Henning Schmidt , Wolfgang Berdel
European Respiratory Journal 42 2908
2013
Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)
Peter Dreger , Anita Schmitt , Thomas Luft , Sascha Dietrich
Blood 136 11 -12
2020
Comprehensive Comparison of Early Relapse and End-Stage Relapsed Refractory Multiple Myeloma
Matthias Schlesner , Hartmut Goldschmidt , Benedikt Brors , Alexandra M Poos
Blood 136 1 -1
1
2020
Impact of Novel Therapies on CD4-T-Cell-Numbers and Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma
Michael Hundemer , Elias K Mai , Hartmut Goldschmidt , Marc S. Raab
Blood 136 14 -14
2020
Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile
Stephan Stilgenbauer , Richard Rosenquist , Mattias Vesterlund , Matthias Ganzinger
Blood 136 10 -11
2020
Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile
Stephan Stilgenbauer , Richard Rosenquist , Mattias Vesterlund , Matthias Ganzinger
Blood 136 10 -11
2020
Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile
Stephan Stilgenbauer , Richard Rosenquist , Mattias Vesterlund , Matthias Ganzinger
Blood 136 10 -11
2020
A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy.
Jorge E. Cortes , Jessica Altman , Ellen K. Ritchie , Richard A. Larson
Journal of Clinical Oncology 35
6
2017
Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible
Torsten Kessler , Steffen Koschmieder , Christoph Schliemann , Martina Crysandt
Blood 132 5176 -5176
2018
Novel PDGFRA Point Mutations in Hypereosinophilic Syndrome Induce Growth Factor Independence and Leukemia in Vitro and In Vivo.
Christian Elling , Philipp Erben , Christoph Walz , Marie Frickenhaus
Blood 114 ( 22) 767 -767
2
2009
Neuropharmacology and management of chemotherapy-induced nausea and vomiting in patients with breast cancer.
Karin Jordan , Judith Schaffrath , Franziska Jahn , Carsten Mueller-Tidow
Breast Care 9 ( 4) 246 -253
8
2014
The Cyclin Interactor p26INCA1 Regulates the Hematopoietic Stem Cell Pool Via CDK Inhibition.
Nicole Baeumer , Sven Diederichs , Steffen Koschmieder , Boris V. Skryabin
Blood 110 ( 11) 637 -637
2007
Activation of AKT1 in Hematopoietic Stem Cells Causes a Myeloproliferative Disease in a Tet-Inducible Mouse Model.
Christian Brandts , Miriam Rode , Beate Lindtner , Gabriele Koehler
Blood 112 ( 11) 1356 -1356
2008